The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! About 373,838 shares traded hands or 61.26% up from the average. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 58.09% since April 18, 2016 and is uptrending. It has outperformed by 53.66% the S&P500.
The move comes after 6 months positive chart setup for the $177.72 million company. It was reported on Nov, 18 by Barchart.com. We have $22.30 PT which if reached, will make NASDAQ:ZYNE worth $79.97 million more.
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage
Out of 5 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 7 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Canaccord Genuity initiated it with “Buy” rating and $35 target price in Monday, September 14 report. H.C. Wainwright initiated the shares of ZYNE in a report on Friday, October 7 with “Buy” rating. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) earned “Overweight” rating by Piper Jaffray on Monday, August 31. The firm earned “Outperform” rating on Tuesday, September 8 by Oppenheimer. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has “Outperform” rating given on Thursday, November 12 by Oppenheimer. Jefferies initiated it with “Buy” rating and $33 target price in Monday, August 31 report.
According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”
More news for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on July 03, 2015. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on July 31, 2015 is yet another important article.
ZYNE Company Profile
Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.